3,931 followers
“In France, over half of the population with cystic fibrosis without a F508del variant responded to elexacaftor–tezacaftor–ivacaftor, with most responders having no FDA-approved variant” www.thelancet.com/journals/lan...
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Overview of attention for article published in The Lancet Respiratory Medicine, August 2024
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (75th percentile)
Readers on
- mendeley
- 49 Mendeley